Shares of Fulcrum Therapeutics (NASDAQ:FULC) rose on Friday after Leerink Partners upgraded the Cambridge, Massachusetts-based biopharma, citing a favorable risk-reward setup ahead of a trial readout ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the ...

This could give Novartis' drug a slight advantage. However, Leerink Partners analyst Joseph Schwartz said the FDA will consider removing the liver monitoring requirement for Filspari in late August.

A new sales organization for Israel bonds, under the direction of Dr. Joseph J. Schwartz, executive vice-chairman of the United Jewish Appeal, is now in the process of formation in this country ...